Aminoglycoside-induced translational read-through in disease: Overcoming nonsense mutations by pharmacogenetic therapy

L. V. Zingman, S. Park, T. M. Olson, A. E. Alekseev, A. Terzic

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations

Abstract

A third of inherited diseases result from premature termination codon mutations. Aminoglycosides have emerged as vanguard pharmacogenetic agents in treating human genetic disorders due to their unique ability to suppress gene translation termination induced by nonsense mutations. In preclinical and pilot clinical studies, this therapeutic approach shows promise in phenotype correction by promoting otherwise defective protein synthesis. The challenge ahead is to maximize efficacy while preventing interaction with normal protein production and function.

Original languageEnglish (US)
Pages (from-to)99-103
Number of pages5
JournalClinical pharmacology and therapeutics
Volume81
Issue number1
DOIs
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Aminoglycoside-induced translational read-through in disease: Overcoming nonsense mutations by pharmacogenetic therapy'. Together they form a unique fingerprint.

Cite this